Skip to main content
Cell Cycle logoLink to Cell Cycle
. 2011 Apr 1;10(7):1132–1143. doi: 10.4161/cc.10.7.15207

Microarray analysis of the mammalian thromboxane receptor-Trypanosoma cruzi interaction

Herbert B Tanowitz 1,2,, Aparna Mukhopadhyay 3, Anthony W Ashton 4, Michael P Lisanti 5, Fabiana S Machado 6, Louis M Weiss 1,2, Shankar Mukherjee 1,
PMCID: PMC3100887  PMID: 21364319

Abstract

Trypanosoma cruzi, the etiological agent of Chagas disease, causes vasculopathy and cardiomyopathy in humans and is associated with elevated levels of several vasoactive molecules such as nitric oxide, endothelin-1 and thromboxane A2 (TXA2). Parasite derived TXA2 modulates vasculopathy and other pathophysiological features of chagasic cardiomyopathy. Previously, we demonstrated that in response to infection with T. cruzi, TXA2 receptor (TP) null mice displayed increased parasitemia; mortality and cardiac pathology compared with wild type (WT) and TXA2 synthase null mice. In order to further study the role of TXA2-TP signaling in the development of Chagas disease, GeneChip microarrays were used to detect transcriptome changes in rat fat pad endothelial cells (RFP-ECs) which is incapable of TXA2 signaling (TP null) to that of control (wild type) and RFP-EC with reconstituted TP expression. Genes that were significantly regulated due to infection were identified using a time course of 2, 18 and 48 hrs post infection. We identified several key genes such as suppressor of cytokine signaling (SOCS-5), several cytokines (CSF-1, CXCF ligands) and MAP kinases (MAPK-1, Janus kinase) that were upregulated in the absence of TP signaling. These data underscore the importance of the interaction of the parasite with mammalian TP and may explain the increased mortality and cardiovascular pathology observed in infected TP null mice.

Key words: Trypanosoma cruzi, Chagel disease, thromboxane signaling, microarray, suppressor of cytokine signaling

Introduction

Eicosanoids are a family of lipid mediators that participate in a wide range of biological activities including vascular tone, inflammation, ischemia and tissue homeostasis.1 In mammals, the biosynthetic pathways for these important biological mediators are dependent upon liberation of arachidonic acid from the inner leaflet of the plasma membrane. Thromboxane A2 (TxA2), an eicosanoid generated during arachidonic acid metabolism, is the most potent vasoconstrictor known and acts via its receptors TPα and its splice variant TPβ, both of which are expressed on human endothelial cells (ECs). Several parasitic organisms are known to produce eicosanoids, many of which are known to modulate host response and the progress of an infection.26

Infection with the protozoan parasite Trypanosoma cruzi causes Chagas disease, characterized by acute myocarditis and vasculitis that evolves into a chronic cardiomyopathy in 15 to 30% of infected persons. Chagasic cardiomyopathy is an important cause of morbidity and mortality in endemic areas of Mexico, Central and South America.7,8 Transmission to humans may occur by several means including natural transmission via the insect vector, blood transfusion, laboratory accidents, organ transplantation, congenital transmission9,10 and ingestion of contaminated food and water.11 Chagas disease is also recognized as an opportunistic infection in immune-compromised individuals including those with HIV/AIDS.12

The parasite has a complex life cycle involving a mammalian host and a insect vector.7 The insect forms include epimastigotes, which multiply extracellularly, inside the insect midgut and give rise to infective non-dividing metacyclic trypomastigotes (MT). The insect introduces MTs into the mammalian host while taking a blood meal, through its feces near the punctured skin. The MTs immediately transforms into non-dividing, blood form trypomastigotes (BFT). BFTs can infect a variety of host cell types and multiply intracellularly as amastigotes.13 Amastigotes are released as infected cells rupture and transform back to BFTs, which infect adjacent tissues or are swept into the blood and lymphatics to remote areas of the body. In the cardiovascular system cardiac myocytes, cardiac fibroblasts, ECs and vascular smooth muscle cells are readily infected by this parasite.

Acute T. cruzi infection results in the upregulation of the inflammatory responses in many tissues and has been studied most extensively in the heart. During acute infection there is an increased expression of cytokines,14 chemokines,15 endothelin-1,16,17 vascular adhesion molecules18 and nitric oxide synthases19 which is accompanied by an intense inflammatory infiltrate, myonecrosis, pseudocyst formation, vasculitis and platelet activation and aggregation. Chronic chagasic cardiomyopathy is an example of a dilated cardiomyopathy associated with chronic inflammation and fibrosis, myocytolysis, congestive heart failure and thombo-embolic events. Notably, few parasites are observed in the myocardium during the chronic phase. Many of the features of acute and chronic Chagas disease are also associated with the activation of TXA2 signaling pathway via its receptors.20

The role of TXA2 in the pathogenesis of T. cruzi infection was suggested in 1990,21 and recently examined in more detail in reference 22. Our laboratory demonstrated that all T. cruzi life cycle forms were capable of synthesizing TXA2 thereby modulating vasculopathy and other features of chagasic cardiomyopathy including inflammation and platelet activation.22 Additionally, we demonstrated that majority of circulating TXA2 in T. cruzi-infected thromboxane synthase (TXA2S)-null mice was parasite-derived. T. cruzi infection of TP null mice resulted in increased peripheral parasitemia and mortality. Moreover, infection of ECs obtained from TP null mice displayed higher intracellular parasitism compared with wild-type uninfected cells,22 suggesting that the TXA2-TP signaling plays an important role in Chagas disease. These observations suggested that parasite-derived TXA2 is sufficient to stimulate host TP to ensure normal disease progression via stimulation of host TP to affect parasitemia and host survival. The parasite-derived TXA2 may not directly participate in the inflammatory process of the host, but rather contribute to the balance between the rate of parasite proliferation and continued survival of the host so that the disease can progress to the chronic stage. Previously, we demonstrated that TP stimulation inhibits the proinflammatory effects of TNFα via a Gαq mediated mechanism.22

The nature of the signaling pathways resulting from TP activation that control parasite growth and replication is not entirely known, although activation of Gαq appears to be important.22,23 We sought to determine the potential molecular mechanisms by which the parasite-derived TXA2 modulates Chagas disease progression and limit collateral damage to organs. Thus, we performed GeneChip microarray analysis on rat fat pad ECs with normal TP (WT-EC) and TPα null-EC24 responses to TXA2 signaling and compared to null-EC reconstituted with the human TPα isoform (TPα-EC). The changes in the transcription profile were compared with matched uninfected and infected WT-EC. Rats do not express TPβ, therefore, TPα null ECs are functionally incapable of TXA2 signaling. We monitored the host response to TP receptor null environment over a time course of 2, 18 and 48 h post infection (p.i.).

Results

TP null endothelial cells (ECs) are functionally deficient of TP activation.

We employed immunoflourescence to detect the expression and abundance of TP in RFPECs. Since, TP null ECs were a functional mutant and not a genetic knockout,24 we could detect a small amount of TP expression in these cells with anti-human TP antibody that also recognizes rat TPs. However, the abundance of TP in TP null ECs was approximately 42% of that of WT-EC and 29% of that of the TP reconstituted (TPα-EC) ECs (Fig. 1). We also analyzed the expression of TP by immunoblotting using the same antibody and found that TP null ECs contain significantly less TP as compared to either the WT-ECGrTPα-EC. Conversely, re-expression of the human TPα isoform in null-EC resulted in levels of expression similar to those observed in WT-EC indicating physiological levels of expression were achieved in TPα-EC (Fig. 2A). TP expression in these cells was not regulated as a result of either infection with T. cruzi treatment with 50 nM IBOP, a TP receptor against (Fig. 2B). We evaluated the functional status of TP in these cells by stimulating with 50 nM IBOP, a thromboxane-mimetic agent and measuring the activation of ERK pathway by immunoblotting using anti phospho ERK antibody.25 Both WT-EC and TPα-EC expressed high levels of phospho ERK when stimulated with IBOP indicating an intact TP signaling pathways in these cells. However, we could not detect ERK activation in TP null ECs stimulated with IBOP (Fig. 2C). These results indicate that reconstitution of TP null ECs with ectopic expression of human TPα isoforms are a reliable system to analyze TP signaling as functional receptors with appropriate coupling. Thus they were employed to determine the role of prostanoid signaling associated with T. cruzi infection.

Figure 1.

Figure 1

Detection of TP in WT-EC (A), TP null (B) and TPα-EC (C) by immunoflourescence using anti TPα antibody. Both WT-EC and TP null with transfected human TPα gene expressed abundant TPα protein as compared to that of TP null ECs. The faint expression of TPα in TP null EC may be due to the fact that TP null EC are functional but not genetic knockouts or it may be due to reaction of TPα antibody with a related protein as no primary antibody control staining could detect any background staining with TPα antibody (D).

Figure 2.

Figure 2

TP expression in WT-EC, TP null and TPα-EC by immunoblotting. (A) TP expression in these cells was not regulated by either infection with T. cruzi or when these cells were stimulated with a TP receptor against, IBOP (B) TP expressed in TP null and TPα EC were functional as ERK activation was observed when these cells were stimulated with IBOP (C) Beta actin was used as an equal loading control for all immunoblots and its expression was unaffected by experimental conditions (the controls for B and C not shown).

Significantly upregulated genes in T. cruzi infection and those that are also dependent on TP activation.

In order to evaluate significantly upregulated genes in the setting of T. cruzi infection and those that are also dependent on TP activation, we compared the entire data set including all target ECs (i.e., WT-EC, TP null EC and TPα-EC) and conditions (control vs. infected) at all time points. Data was normalized to mean values and statistical significance was determined using ANOVA (6,799 genes). In the selection process, the following criteria were used: first, genes were selected that were upregulated in infected TP null ECs by at least 1.5-fold when compared with the infected WT ECs, second, we selected only those genes from infected TPα-ECs that had expression values between 1–1.5-fold to that of infected WT ECs (445 genes). Third, we selected only those genes, which showed regulation when compared to the matched control (162 genes). Using these criteria we were able to isolate genes that were upregulated because of absence of the TXA2-TP signaling pathway during the course of T. cruzi infection. Comparing with the regulated genes observed in the reconstituted cells with TPα receptor expression resulted in the selection of those genes that were expressed at normal levels when the TXA2-TP signaling pathway was restored. Finally we used the Ingenuity Pathways Analysis to classify genes according to their function.

After trimming control and unknown genes from the list, we obtained 136 genes (Table 1) that were significantly upregulated because of TP null phenotype. These genes are believed to be otherwise downregulated if the TP pathway were intact as in the WT or when we reconstitute the cells with the TP receptor. Table 1 provides a list of upregulated genes and their functions.

Table 1.

The genes that were upregulated (>1.5-fold) a result of T. cruzi infection in the absence of thromboxane signaling.

ID Gene Description Location Family
1387316_at CXCL2 chemokine (C-X-C motif) ligand 2 Extracellular Space cytokine
1380583_s_at CSF1 colony stimulating factor 1 (macrophage) Extracellular Space cytokine
1379271_at SOCS5* suppressor of cytokine signaling 5 Extracellular Space cytokine
1390555_at SOCS5* suppressor of cytokine signaling 5 Extracellular Space cytokine
1387101_at ACSL4 acyl-CoA synthetase long-chain family member 4 Cytoplasm enzyme
1384115_at ACOT2 acyl-CoA thioesterase 2 Cytoplasm enzyme
1370902_at AKR1B15 aldo-keto reductase family 1, member B15 Cytoplasm enzyme
1368916_at ASL argininosuccinate lyase Cytoplasm enzyme
1375595_at ARIH1 ariadne homolog, ubiquitin-conjugating enzyme E2 binding protein, 1 (Drosophila) Cytoplasm enzyme
1369967_at CS citrate synthase Cytoplasm enzyme
1376754_at CARS cysteinyl-tRNA synthetase Cytoplasm enzyme
1369984_at COX17 COX17 cytochrome c oxidase assembly homolog (S. cerevisiae) Cytoplasm enzyme
1397304_at IGTP interferon gamma induced GTPase Cytoplasm enzyme
1372599_at MGST2 microsomal glutathione S-transferase 2 Cytoplasm enzyme
1372177_at MOCS2 molybdenum cofactor synthesis 2 Cytoplasm enzyme
1370678_s_at MAOA monoamine oxidase A Cytoplasm enzyme
1383899_at NEDD4 neural precursor cell expressed, developmentally downregulated 4 Cytoplasm enzyme
1373418_at EPRS glutamyl-prolyl-tRNA synthetase Cytoplasm enzyme
1382537_at RRAGC* Ras-related GTP binding C Cytoplasm enzyme
1371723_at RRAGC* Ras-related GTP binding C Cytoplasm enzyme
1394077_at RND3 Rho family GTPase 3 Cytoplasm enzyme
1389468_at RPIA ribose 5-phosphate isomerase A Cytoplasm enzyme
1383004_at AHCYL1 adenosylhomocysteinase-like 1 Cytoplasm enzyme
1388574_at WARS tryptophanyl-tRNA synthetase Cytoplasm enzyme
1373037_at UBE2L6 ubiquitin-conjugating enzyme E2L 6 Cytoplasm enzyme
1371537_at B4GALT5 UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase, polypeptide 5 Cytoplasm enzyme
1385695_at LOXL3 lysyl oxidase-like 3 Extracellular Space enzyme
1370144_at GTPBP4 GTP binding protein 4 Nucleus enzyme
1374725_at MOV10 Mov10, Moloney leukemia virus 10, homolog (mouse) Nucleus enzyme
1391608_at PARN poly(A)-specific ribonuclease (deadenylation nuclease) Nucleus enzyme
1384157_at ARL8B* ADP-ribosylation factor-like 8B Plasma Membrane enzyme
1397815_at ARL8B* ADP-ribosylation factor-like 8B Plasma Membrane enzyme
1387925_at ASNS asparagine synthetase unknown enzyme
1374489_at GTPBP2 GTP binding protein 2 unknown enzyme
1399160_a_at UBE2D3 (includes EG:66105) ubiquitin-conjugating enzyme E2D 3 (UBC4/5 homolog, yeast) unknown enzyme
1371710_at ETNK1 ethanolamine kinase 1 Cytoplasm kinase
1380110_at JAK2 Janus kinase 2 Cytoplasm kinase
1374550_at MKNK1 MAP kinase interacting serine/threonine kinase 1 Cytoplasm kinase
1388521_at ALDH18A1 aldehyde dehydrogenase 18 family, member A1 Cytoplasm kinase
1373943_at STK4 serine/threonine kinase 4 Cytoplasm kinase
1382541_at ALK anaplastic lymphoma receptor tyrosine kinase Plasma Membrane kinase
1367788_at PHKG2 phosphorylase kinase, gamma2 (testis) unknown kinase
1387605_at CASP12 (includes EG:12364) caspase 12 Cytoplasm peptidase
1387818_at CASP4 caspase 4, apoptosis-related cysteine peptidase Cytoplasm peptidase
1398803_at DYNC1H1 dynein, cytoplasmic 1, heavy chain 1 Cytoplasm peptidase
1367786_at PSMB8 proteasome (prosome, macropain) subunit, beta type, 8 (large multifunctional peptidase 7) Cytoplasm peptidase
1378679_at USP25 ubiquitin specific peptidase 25 unknown peptidase
1374447_at USP9X ubiquitin specific peptidase 9, X-linked Plasma Membrane peptidase
1399125_at INPP1 inositol polyphosphate-1-phosphatase Cytoplasm phosphatase
1367624_at ATF4 activating transcription factor 4 (tax-responsive enhancer element B67) Nucleus transcription regulator
1379483_at BHLHE40 basic helix-loop-helix family, member e40 Nucleus transcription regulator
1387800_at DAXX death-domain associated protein Nucleus transcription regulator
1375205_at KAT2B K(lysine) acetyltransferase 2B Nucleus transcription regulator
1372797_at PQBP1 polyglutamine binding protein 1 Nucleus transcription regulator
1392828_at MED12 mediator complex subunit 12 Nucleus transcription regulator
1383339_at C19ORF2 chromosome 19 open reading frame 2 Nucleus transcription regulator
1399066_at TMF1 TATA element modulatory factor 1 Cytoplasm transcription regulator
1393144_at NMI N-myc (and STAT) interactor Cytoplasm transcription regulator
1393257_at CUGBP1 CUG triplet repeat, RNA binding protein 1 Nucleus translation regulator
1368967_at EIF2B3 eukaryotic translation initiation factor 2B, subunit 3gamma, 58 kDa Cytoplasm translation regulator
1373917_at ETF1 eukaryotic translation termination factor 1 Cytoplasm translation regulator
1387202_at ICAM1 intercellular adhesion molecule 1 Plasma Membrane transmembrane receptor
1388071_x_at HLA-C* major histocompatibility complex, class I, C Plasma Membrane transmembrane receptor
1388071_x_at HLA-C* major histocompatibility complex, class I, C Plasma Membrane transmembrane receptor
1369065_a_at ATP2A2 ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 Cytoplasm transporter
1387664_at ATP6V1B2 ATPase, H+ transporting, lysosomal 56/58 kDa, V1 subunit B2 Cytoplasm transporter
1379255_at ATP6AP2* ATPase, H+ transporting, lysosomal accessory protein 2 Cytoplasm transporter
1379255_at ATP6AP2* ATPase, H+ transporting, lysosomal accessory protein 2 Cytoplasm transporter
1367503_at BCAP31 B-cell receptor-associated protein 31 Cytoplasm transporter
1368881_at BET1 blocked early in transport 1 homolog (S. cerevisiae) Cytoplasm transporter
1386934_at SLC6A8 solute carrier family 6 (neurotransmitter transporter, creatine), member 8 Cytoplasm transporter
1368391_at SLC7A1* solute carrier family 7 (cationic amino acid transporter, y+ system), member 1 Plasma Membrane transporter
1368392_at SLC7A1* solute carrier family 7 (cationic amino acid transporter, y+ system), member 1 Plasma Membrane transporter
1368392_at SLC7A1* solute carrier family 7 (cationic amino acid transporter, y+ system), member 1 Plasma Membrane transporter
1368391_at SLC7A1* solute carrier family 7 (cationic amino acid transporter, y+ system), member 1 Plasma Membrane transporter
1370014_at STX4 syntaxin 4 Plasma Membrane transporter
1371432_at VAT1 vesicle amine transport protein 1 homolog (T. californica) Plasma Membrane transporter
1387026_at SMC1A structural maintenance of chromosomes 1A Nucleus transporter
1368732_at TAP2 transporter 2, ATP -binding cassette, sub-family B (MDR/TAP) Cytoplasm transporter
1388903_at DYNLT3 dynein, light chain, Tctex-type 3 Cytoplasm other
1372091_at MID1IP1 MID1 interacting protein 1 [gastrulation specific G12 homolog (zebrafish)] Cytoplasm other
1371028_at TGOLN2 (includes EG:10618) trans-golgi network protein 2 Cytoplasm other
1369031_at IL18BP* interleukin 18 binding protein Extracellular Space other
1369031_at IL18BP* interleukin 18 binding protein Extracellular Space other
1388983_at C15ORF24 chromosome 15 open reading frame 24 Extracellular Space other
1389577_at CIRH1A cirrhosis, autosomal recessive 1A (cirhin) Nucleus other
1382326_at DEDD death effector domain containing Nucleus other
1368947_at GADD45A growth arrest and DNA-damage-inducible, alpha Nucleus other
1388792_at GADD45G growth arrest and DNA-damage-inducible, gamma Nucleus other
1372945_at ING3 inhibitor of growth family, member 3 Nucleus other
1374551_at IFI35 interferon-induced protein 35 Nucleus other
1372409_at MAD2L1BP MAD2L1 binding protein Nucleus other
1376144_at PARP9 poly (ADP-ribose) polymerase family, member 9 Nucleus other
1395523_at RBMX RNA binding motif protein, X-linked Nucleus other
1390218_at MEAF6 MYST/Esa1-associated factor 6 Nucleus other
1388436_at SNRPA small nuclear ribonucleoprotein polypeptide A Nucleus other
1387824_at SFRS12 splicing factor, arginine/serine-rich 12 Nucleus other
1390290_at SURF6 surfeit 6 Nucleus other
1371968_at TMBIM4 transmembrane BAX inhibitor motif containing 4 Nucleus other
1379249_at WTAP Wilms tumor 1 associated protein Nucleus other
1393127_at ZNF358 zinc finger protein 358 Nucleus other
1368921_a_at CD44 CD44 molecule (Indian blood group) Plasma Membrane other
1371939_at CAPRIN1 cell cycle associated protein 1 Plasma Membrane other
1373182_at CLDN12 claudin 12 Plasma Membrane other
1387995_a_at IFITM3 interferon induced transmembrane protein 3 (1-8U) Plasma Membrane other
1388347_at LY6E lymphocyte antigen 6 complex, locus E Plasma Membrane other
1393915_at LPCAT3 lysophosphatidylcholine acyltransferase 3 Plasma Membrane other
1388196_at NCKAP1 NCK-associated protein 1 Plasma Membrane other
1374525_at RAPH1 Ras association (RalGDS/AF-6) and pleckstrin homology domains 1 Plasma Membrane other
1372489_at SLMAP sarcolemma associated protein Plasma Membrane other
1375697_at MLEC malectin Plasma Membrane other
1375641_at ARPC5L (includes EG:296710) actin related protein 2/3 complex, subunit 5-like unknown other
1382110_at CNPY3 canopy 3 homolog (zebrafish) unknown other
1389573_at CHAC1 ChaC, cation transport regulator homolog 1 (E. coli) unknown other
1372361_at CCDC22 coiled-coil domain containing 22 unknown other
1375174_at DPY19L1 dpy-19-like 1 (C. elegans) unknown other
1398925_at FTSJD2 FtsJ methyltransferase domain containing 2 unknown other
1373956_at FUNDC1 FUN14 domain containing 1 unknown other
1383255_at GPKOW G patch domain and KOW motifs unknown other
1370975_at KDM3A lysine (K)-specific demethylase 3A unknown other
1386478_at MCART2 mitochondrial carrier triple repeat 2 unknown other
1389162_at NFU1 NFU1 iron-sulfur cluster scaffold homolog (S. cerevisiae) unknown other
1393097_at RPRD1A regulation of nuclear pre-mRNA domain containing 1A unknown other
1388900_at RGD1566118 RGD1566118 unknown other
1372585_at RGD1566254* RGD1566254 unknown other
1372585_at RGD1566254* RGD1566254 unknown other
1375955_at RNF114 ring finger protein 114 unknown other
1399070_at SETD5 SET domain containing 5 unknown other
1389984_at LOC681740 similar to jumonji protein unknown other
1371531_at LOC678880 similar to mammalian retrotransposon derived 8b unknown other
1393096_at HCG 21078 ribosomal protein L27a pseudogene 6 unknown other
1383793_at TMCC1 transmembrane and coiled-coil domain family 1 unknown other
1394842_at TMEM19 transmembrane protein 19 unknown other
1373136_at ZUFSP zinc finger with UFM1-specific peptidase domain unknown other

Significantly, downregulated genes in T. cruzi infection that are also dependent on TP activation.

Using a similar approach, we found 106 genes to be significantly downregulated in TP null cells due to T. cruzi infection (Table 2). These genes are believed to be otherwise upregulated if the TP pathway were intact as in the wild-type when we reconstitute the cells with the TPα receptor.

Table 2.

The genes that were downregulated (>1.5-fold) due to T. cruzi infection in the absence of thromboxane signaling.

ID Symbol Entrez gene name Location Type(s)
1367629_at COX7A2 cytochrome c oxidase subunit VIIa polypeptide 2 (liver) Cytoplasm enzyme
1380500_s_at FKBP2 FK506 binding protein 2, 13 kDa Cytoplasm enzyme
1370829_at FNTB farnesyltransferase, CAAX box, beta Cytoplasm enzyme
1375913_at GALNT2 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 2 (GalNAc-T2) Cytoplasm enzyme
1373675_at GLRX2 glutaredoxin 2 Cytoplasm enzyme
1386982_at MGAT2 mannosyl (alpha-1,6-)-glycoprotein beta-1,2-N-acetylglucosaminyltransferase Cytoplasm enzyme
1389288_at NDUFA2 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 2, 8 kDa Cytoplasm enzyme
1370012_at PTGIS prostaglandin I2 (prostacyclin) synthase Cytoplasm enzyme
1389655_at PTRH2 peptidyl-tRNA hydrolase 2 Cytoplasm enzyme
1376066_at RND3 Rho family GTPase 3 Cytoplasm enzyme
1367668_a_at SCD2 stearoyl-Coenzyme A desaturase 2 Cytoplasm enzyme
1386392_at ANAPC10 anaphase promoting complex subunit 10 Nucleus enzyme
1397508_at DDX18 DEAD (Asp-Glu-Ala-Asp) box polypeptide 18 Nucleus enzyme
1371449_at PIN1 peptidylprolyl cis/trans isomerase, NIMA-interacting 1 Nucleus enzyme
1372725_at PLSCR2 phospholipid scramblase 2 Nucleus enzyme
1398899_at POLR2C polymerase (RNA) II (DNA directed) polypeptide C, 33 kDa Nucleus enzyme
1377338_at RAD1 RAD1 homolog (S. pombe) Nucleus enzyme
1372476_at FADS3 fatty acid desaturase 3 Plasma Membrane enzyme
1399111_at CYB561D2 cytochrome b-561 domain containing 2 unknown enzyme
1370075_at DHFR dihydrofolate reductase unknown enzyme
1376314_at UBE2Q2 ubiquitin-conjugating enzyme E2Q family member 2 unknown enzyme
1367631_at CTGF connective tissue growth factor Extracellular Space growth factor
1368470_at GGH gamma-glutamyl hydrolase (conjugase, folylpolygammaglutamyl hydrolase) Cytoplasm peptidase
1382385_at PSMC6 proteasome (prosome, macropain) 26 S subunit, ATPase, 6 Nucleus peptidase
1378679_at USP25 ubiquitin specific peptidase 25 unknown peptidase
1372685_at CDKN3 cyclin-dependent kinase inhibitor 3 Nucleus phosphatase
1368917_at NUDT1 nudix (nucleoside diphosphate linked moiety X)-type motif 1 Extracellular Space phosphatase
1386065_at ANKRD57 ankyrin repeat domain 57 Nucleus transcription regulator
1384742_at ATRX alpha thalassemia/mental retardation syndrome X-linked (RAD54 homolog, S. cerevisiae) Nucleus transcription regulator
1380558_at DLX3 distal-less homeobox 3 Nucleus transcription regulator
1379969_at FOXJ2 forkhead box J2 Nucleus transcription regulator
1383377_at GABPA GA binding protein transcription factor, alpha subunit 60 kDa Nucleus transcription regulator
1377858_at PRDM2 PR domain containing 2, with ZNF domain Nucleus transcription regulator
1391212_at TCEAL1 transcription elongation factor A (SII)-like 1 Nucleus transcription regulator
1376197_at TCF7 transcription factor 7 (T-cell specific, HMG-box) Nucleus transcription regulator
1394591_at ZNF207 zinc finger protein 207 Nucleus transcription regulator
1379967_at ZNF367 zinc finger protein 367 Nucleus transcription regulator
1367713_at EIF2S1 eukaryotic translation initiation factor 2, subunit 1 alpha, 35 kDa Cytoplasm translation regulator
1375135_at GCN1L1 GCN1 general control of amino-acid synthesis 1-like 1 (yeast) Cytoplasm translation regulator
1392888_at GPC4 glypican 4 Plasma Membrane transmembrane receptor
1388416_at LRP1 low density lipoprotein-related protein 1 (alpha-2-macroglobulin receptor) Plasma Membrane transmembrane receptor
1368869_at AKAP12 A kinase (PRKA) anchor protein 12 Cytoplasm transporter
1398554_at ATP6V0B ATPase, H+ transporting, lysosomal 21 kDa, V0 subunit b Cytoplasm transporter
1379730_at ATP6V1H ATPase, H+ transporting, lysosomal 50/57 kDa, V1 subunit H Cytoplasm transporter
1368977_a_at FXC1 fracture callus 1 homolog (rat) Cytoplasm transporter
1388796_at GOSR1 golgi SNAP receptor complex member 1 Cytoplasm transporter
1370296_at SCP2 sterol carrier protein 2 Cytoplasm transporter
1388519_at SEC61B Sec61 beta subunit Cytoplasm transporter
1397740_at SFXN1 sideroflexin 1 Cytoplasm transporter
1372834_at VPS4B vacuolar protein sorting 4 homolog B (S. cerevisiae) Cytoplasm transporter
1370934_at NUP153 nucleoporin 153 kDa Nucleus transporter
1382643_at SNX16 sorting nexin 16 unknown transporter
1384339_s_at CSNK2A1 casein kinase 2, alpha1 polypeptide Cytoplasm kinase
1378282_at CSNK2A2 casein kinase 2, alpha prime polypeptide Cytoplasm kinase
1379433_at PIK3C2A phosphoinositide-3-kinase, class 2, alpha polypeptide Cytoplasm kinase
1377832_at PLK4 polo-like kinase 4 (Drosophila) Cytoplasm kinase
1382707_at RPS6KA3 ribosomal protein S6 kinase, 90 kDa, polypeptide 3 Cytoplasm kinase
1383926_at BUB1B budding uninhibited by benzimidazoles 1 homolog beta (yeast) Nucleus kinase
1389166_at CIB2 calcium and integrin binding family member 2 unknown kinase
1380682_at MEX3B mex-3 homolog B (C. elegans) unknown kinase
1389967_at ARL6IP1 ADP-ribosylation factor-like 6 interacting protein 1 Cytoplasm other
1369588_a_at ATPIF1 ATPase inhibitory factor 1 Cytoplasm other
1374449_at CDCA3 cell division cycle associated 3 Cytoplasm other
1375186_at DPH3 DPH3, KTI11 homolog (S. cerevisiae) Cytoplasm other
1388850_at HSP90AA1 heat shock protein 90 kDa alpha (cytosolic), class A member 1 Cytoplasm other
1388851_at HSPA9 heat shock 70 kDa protein 9 (mortalin) Cytoplasm other
1372389_at IER2 immediate early response 2 Cytoplasm other
1392065_at KIF18A kinesin family member 18A Cytoplasm other
1391063_at KIF23 kinesin family member 23 Cytoplasm other
1392901_at LRRC1 leucine rich repeat containing 1 Cytoplasm other
1371649_at MRPS24 mitochondrial ribosomal protein S24 Cytoplasm other
1377779_at PDCL3 phosducin-like 3 Cytoplasm other
1392983_at PSMD12 proteasome (prosome, macropain) 26 S subunit, non-ATPase, 12 Cytoplasm other
1387064_at PXMP3 peroxisomal membrane protein 3, 35 kDa Cytoplasm other
1384089_at RABGEF1 RAB guanine nucleotide exchange factor (GEF) 1 Cytoplasm other
1384551_at RANBP6 RAN binding protein 6 Cytoplasm other
1392232_at RPS13 ribosomal protein S13 Cytoplasm other
1388705_at SELM selenoprotein M Cytoplasm other
1390767_at SSR1 signal sequence receptor, alpha Cytoplasm other
1368041_at SYNJ2BP synaptojanin 2 binding protein Cytoplasm other
1383568_at TUBE1 tubulin, epsilon 1 Cytoplasm other
1389533_at FBLN2 fibulin 2 Extracellular Space other
1367912_at LTBP1 latent transforming growth factor beta binding protein 1 Extracellular Space other
1384264_at MYH14 myosin, heavy chain 14, non-muscle Extracellular Space other
1371873_at ANP32E acidic (leucine-rich) nuclear phosphoprotein 32 family, member E Nucleus other
1374323_at BCCIP BRCA2 and CDKN1A interacting protein Nucleus other
1371953_at CCNG2 cyclin G2 Nucleus other
1389506_x_at CDC20 cell division cycle 20 homolog (S. cerevisiae) Nucleus other
1383958_at CDCA2 cell division cycle associated 2 Nucleus other
1374540_at CDCA7 cell division cycle associated 7 Nucleus other
1388928_at CFL2 cofilin 2 (muscle) Nucleus other
1377172_at GPSM2 G-protein signaling modulator 2 (AGS3-like, C. elegans) Nucleus other
1390384_at H2AFX H2A histone family, member X Nucleus other
1383292_at INCENP inner centromere protein antigens 135/155 kDa Nucleus other
1374794_at KIF15 kinesin family member 15 Nucleus other
1377689_at KNTC1 kinetochore associated 1 Nucleus other
1374051_at NCAPH2 non-SMC condensin II complex, subunit H2 Nucleus other
1393267_at PSIP1 PC4 and SFRS1 interacting protein 1 Nucleus other
1383623_at THYN1 thymocyte nuclear protein 1 Nucleus other
1389305_at ANXA4 annexin A4 Plasma Membrane other
1389145_at CDC42EP2 CDC42 effector protein (Rho GTPase binding) 2 Plasma Membrane other
1372300_at DOK4 docking protein 4 Plasma Membrane other
1368255_at NTM neurotrimin Plasma Membrane other
1370247_a_at PMP22 peripheral myelin protein 22 Plasma Membrane other
1377089_a_at TSPAN5 tetraspanin 5 Plasma Membrane other

Discussion

The pathogenesis of T. cruzi-induced cardiomyopathy and vasculopathy are not fully understood. Over the past decade there have been a number of microarray studies by our laboratory group and others examining the consequences of T. cruzi infection on murine heart,2628 cultured cardiac myocytes,29 myoblasts,30 fibroblasts,31,32 HeLa cells33 and human coronary artery smooth muscle cells.34

In our previous microarray studies, we examined transcriptome changes in infected murine heart in C7BL/6 × 129sv (100 days) and CD-1,26,27 (a time course ranging from 30–180 days, encompassing both in the acute and chronic stages of infection) with the Brazil strain of T. cruzi. Among the genes that were upregulated in the previous studies and the current one includes secretary leukocyte protease inhibitor (SLPI) and Caspase-12. SLPI is an important modulator of inflammatory responses responsible for cardiac remodeling35,36 and was observed to be upregulated in the acute stage (six-fold increase), which waned as the infection evolved into the chronic stage.25 In the present study, we also observed overexpression of SLPI gene, however, we were unable to demonstrate this increase by immunoblotting (data not shown). Interestingly, both our group27 and Garg et al.37 observed that both in vitro and in vivo, among the most repressed genes includes those for oxidative phosphorylation complexes I and IV. In the current study, we also observed repressed cytochrome c oxidase VIIa and NADH dehydrogenase (ubiquinone-1-α subcomplex-1) genes.

The current studies are an outgrowth of our interests in the role of eicosanoids in general and TXA2 signaling in particular in the pathogenesis of Chagas disease. Recently we identified the importance of SOCS (suppressor of cytokine signaling) proteins in T. cruzi infection with respect to arachidonic acid metabolic pathway in the host. We have observed that treatment of acutely infected mice (with Brazil strain) with aspirin (ASA) increased both mortality and parasitemia and this phenomenon was attributable to an increased expression of SOCS-2 in the spleens of infected, ASA-treated mice.38 There are eight SOCS proteins (1–7 and CIS) that negatively regulate cytokine signaling by a variety of mechanisms. In this analysis we found that SOCS-5 is upregulated in TP null ECs. The increase in SOCS-5 may explain the increased mortality found in TP null infected mice as in both the cases, reducing cytokine signaling has a profound effect in loss of innate immunity and hence host survival. SOCS-2 inhibits cytokine signaling by interleukin-6 (IL-6) and growth hormone while SOCS-5 binds to IL-4 receptor and phosphorylated insulin-like growth factor (IGF-I) and promotes in cellular growth and differentiation, and inhibits apoptosis via the Ras and PI3K signaling pathways. Interestingly, SOCS-2 protein was not overexpressed in TP null ECs as was observed in ASA-treated mice (unpublished data). However, there was an increased expression of SOCS-5 protein in the infected TP null ECs as compared to either TP null ECs or WT ECs (Fig. 3). This result indicates the importance of eicosanoid signaling in T. cruzi infection as potential immunemodulators. Inhibition of arachidonic acid metabolic pathway early in the infection, increases parasitemia and mortality by increasing SOCS-2 expression while on the other hand, failure to TP signaling shows similar phenotype by increasing SOCS-5 expression.

Figure 3.

Figure 3

Increased SOCS-5 protein expression was observed in infected TP null EC as compared to WT EC and TPα EC by immunoblotting. However, SOCS-2 levels remained unchanged in TP null environment.

Although T. cruzi is known to produce PGH2, PGF and TXA2, we do not known whether the parasite possess a receptor for these eicosanoids. A deeper understanding of the mechanism of parasitic eicosanoid signaling may provide us clues to the differences between host response in the acute and chronic infection.

Materials and Methods

Parasites.

The Tulahuen strain of T. cruzi was maintained in A/J mice (Jackson Laboratories, Bar Harbor, ME). They were maintained in L6E9 myoblast cultures as previously.39

Materials.

Tissue culture reagents were purchased from Invitrogen (Carlsbad, CA). Plasticware was purchased from Costar (Cambridge, MA). The TP receptor agonist IBOP was obtained from Cayman Chemicals (128719-90-4).

Isolation of primary rat fat pad endothelial cells (RFPECs).

Primary endothelial cells (EC) were isolated from the epididymal fat pad of normal male Sprague Dawley rats as previously described.21 Reconstitution of TP-null RFPEC with the plasmids containing the human TPα coding sequence was performed as previously described,21 using antibiotic selection (150 µg/mL G418) to identify transfected cells. ECs were maintained in humidified incubator at 37°C and 5% CO2 in DMEM high glucose supplemented with 10% FBS and 100 µg/mL penicillin-streptomycin.

Infection of cells.

RFPECs (WT-EC, TP null EC and TPα EC) were infected with trypomastigotes at a multiplicity of infection of ∼2:1 for 2, 18 and 48 h and harvested as previously described.34 To visualize intracellular parasites cells were fixed in methanol and stained with Giemsa.

Genechip reaction.

The infected and the control uninfected cells were washed three times in PBS (pH 7.2) and total RNA were prepared using the TRIZOL (Invitrogen, 15596026) method. The purified RNA was quantitated in Nanodrop (Thermo Fisher Scientific, Waltham, MA) and used for GeneChip analysis. cDNA was synthesized using GeneChip Expression 3′ Amplification one-cycle cDNA synthesis kit (Affymetrix, 900431) using 5 µg of total RNA and T7 oligo (dT) primer. To monitor target labeling, a set of poly-A RNA controls were spiked into the total RNA using GeneChip Eukaryotic Poly-A RNA control kit (Affymetrix, 900433). The double stranded cDNAs were cleaned with the GeneChip sample clean up module (Affymetrix, 900371). Biotin labeled antisense cRNAs were generated by in vitro transcription of cDNA using T7RNA polymerase and biotynylated ribonucleatide analogs using GeneChip Expression 3′ Amplification reagents for IVT labeling (Affymetrix, 900449). The biotinylated cRNAs were further cleaned up using the GeneChip sample clean up module and fragmented to 35–200 bases using the fragmentation buffer as recommended by the manufacturer in the module. Finally, the labeled fragmented cRNAs were hybridized to GeneChip Rat genome 230 2.0 Array (Affymetrix, 900506) for 16 hrs and stained with Streptavidin-Phycoerythrin. Biotynylated anti streptavidin antibody for 1.5 hrs and scanned in GeneChip Scanner 3000, according to the manufacturer's protocol. Hybridization, washing, staining and scanning was performed in the Affymetrix Facility at Albert Einstein College of Medicine according to manufacturer's protocol.

Data analysis.

We analyzed gene expression using Gene Sifter (Geospiza, Inc., Seattle, WA). Briefly, all Affymetrix CHP files were uploaded in Gene Sifter and analysis of the data performed in either of the two following ways. When comparisons of either the conditions or time points were done, analysis was performed using pair wise tool, where the data were normalized with mean and statistical significance determined using t-test. When comparisons were done through all the conditions and all time points, we normalized the data with mean and statistical significance determined using one-way ANOVA. We used Ingenuity Pathways Analysis to classify genes according to their function.

Immunofluorescence.

WT-EC, TP null EC and TPα-EC were grown on coverslip for overnight. Cells were washed in TBS (pH 7.4), fixed in 1% paraformaldehyde (EMS, 15710) for 10 mins and blocked in 10% goat serum (Santa Cruz Biotechnology, sc-2043) in TBS containing 1% Triton X-100 (TBST) for 30 mins. The cells were immunostained with 2 µg/ml anti human TP antibody (Cayman Chemicals, 10004452) for one hour, washed three times in TBST and stained with Alexa 488 conjugated goat anti rabbit secondary antibody (Molecular probes, A11008) and DAPI (Molecular probes, D3571) for one hour in dark. Finally the cells were washed in TBST for three times and observed under an Olympus 1X71 Microscope with 60x oil immersion objective. Immunofluorescence images were captured with a CoolSnap HQ cooled charge-coupled device camera (Roper Scientific, Trenton, NJ) and Cy2 excitation and emission filters using Metamorph software (Molecular Devices, Sunnyvale, CA). Exposure times (100 ms) and brightness adjustments (image normalization) were kept constant for images from different cell types and only secondary antibody negative control.

Immunoblotting.

Whole cell lysates (30 µg protein per lane) were separated by SDS-PAGE under reducing conditions and transferred onto nitrocellulose membrane (Whatman, Dassel, Germany). Immunoblotting was performed using antibodies against human TP (Cayman Chemicals, 10004452), phospho ERK (Cell signaling Technology, 9101S), SOCS-2 (Santa Cruz Biotechnology, sc-9022), SOCS-5 (abcam, 3695) and Caspase 12 (Santa Cruz Biotechnology, sc-5627). Primary antibodies were used at a dilution of 1:500 and anti-rabbit AP-conjugated secondary antibodies (dilution of 1:5,000). For detection of equal loading (as a control), gels were used in parallel and probed with monoclonal β-actin antibody at a dilution of 1:1,000 and HRP-conjugated secondary antibodies at a dilution of 1:5,000.

The bound primary antibodies were visualized by ECL chemiluminescence (Amersham Biosciences, Buckinghamshire, UK) when HRP-conjugated secondary antibodies were used or by the BCIP/NBT color detection system (Promega, Madison, WI) for AP-conjugated secondary antibodies. For these experiments, a representative gel is shown and a Student's t-test was performed and significance of difference was determined as p < 0.05.

Acknowledgements

This work was supported by Scientist Development Grant from the National affiliate of the American Heart Association (SDG 0735252N to S.M.), NIH grant (AI-076248 to H.B.T.). We acknowledge the assistance Vickie Braunstein for cell culture and maintenance.

Abbreviations

AA

arachidonic acid

BFT

blood form trypomastigotes

MT

metacyclic trypomastigotes

PGF

prostaglandin F

PGH2

prostaglandin H2

TXA2

thromboxane A2

TP

TXA2 receptor

TXA2S

TXA2 synthase

RFP-EC

rat fat pad endothelial cells

SOCS

suppressor of cytokine signaling

ERK

extracellular signal-regulated kinase

IBOP

[1S-1α,2α(Z),3β(1E,3S*),4α]-7-[3-[3-hydroxy-4-(4-iodophenoxy)-1-butenyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid

SLPI

secretary leukocyte protease inhibitor

ASA

aspirin

References

  • 1.Haeggström JZ, Rinaldo-Matthis A, Wheelock CE, Wetterholm A. Advances in eicosanoid research, novel therapeutic implications. Biochem Biophys Res Commun. 2010;396:135–139. doi: 10.1016/j.bbrc.2010.03.140. [DOI] [PubMed] [Google Scholar]
  • 2.Noverr MC, Erb-Downward JR, Huffnagle GB. Production of eicosanoids and other oxylipins by pathogenic eukaryotic microbes. Clin Microbiol Rev. 2003;16:517–533. doi: 10.1128/CMR.16.3.517-533.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Belley A, Chadee K. Eicosanoid production by parasites: from pathogenesis to immunomodulation. Parasitol Today. 1995;11:327–334. doi: 10.1016/0169-4758(95)80185-5. [DOI] [PubMed] [Google Scholar]
  • 4.Kilunga Kubata B, Eguchi N, Urade Y, Yamashita K, Mitamura T, Tai K, et al. Plasmodium falciparum produces prostaglandins that are pyrogenic, somnogenic and immunosuppressive substances in humans. J Exp Med. 1998;88:1197–1202. doi: 10.1084/jem.188.6.1197. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Kubata BK, Duszenko M, Kabututu Z, Rawer M, Szallies A, Fujimori K, et al. Identification of a novel prostaglandin F2α synthase in Trypanosoma brucei. J Exp Med. 2000;192:1327–1338. doi: 10.1084/jem.192.9.1327. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Liu LX, Weller PF. Arachidonic acid metabolism in filaria parasites. Exp Parasitol. 1990;71:496–501. doi: 10.1016/0014-4894(90)90076-o. [DOI] [PubMed] [Google Scholar]
  • 7.Tanowitz HB, Kirchhoff V, Simon D, Morris SA, Weiss LM, Wittner M. Chagas' disease. Clin Microbiol Rev. 1992;5:400–419. doi: 10.1128/cmr.5.4.400. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Cantarovich F, Vazquez M, Garcia WD, Abbud Filho M, Herrera C, Villegas Hernandez A. Special infections in organ transplantation in South America. Transplant Proc. 1992;24:1902–1908. [PubMed] [Google Scholar]
  • 9.Leiby DA, Herron RM, Jr, Read EJ, Lenes BA, Stumpf RF. Trypanosoma cruzi in Los Angeles and Miami blood donors: impact of evolving donor demographics on seroprevalence and implications for transfusion transmission. Transfusion. 2002;42:549–555. doi: 10.1046/j.1537-2995.2002.00077.x. [DOI] [PubMed] [Google Scholar]
  • 10.Cantarovich F, Vazquez M, Garcia WD, Abbud Filho M, Herrera C, Villegas Hernandez A. Special infections in organ transplantation in South America. Transplant Proc. 1992;24:1902–1908. [PubMed] [Google Scholar]
  • 11.Pereira KS, Schmidt FL, Barbosa RL, Guaraldo AM, Franco RM, Dias VL, et al. Transmission of Chagas disease (American trypanosomiasis) by food. Adv Food Nutr Res. 2010;59:63–85. doi: 10.1016/S1043-4526(10)59003-X. [DOI] [PubMed] [Google Scholar]
  • 12.Vaidian AK, Weiss LM, Tanowitz HB. Chagas' disease and AIDS. Kinetoplastid Biol Dis. 2004;3:2. doi: 10.1186/1475-9292-3-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Ferreira D, Cortez M, Atayde VD, Yoshida N. Actin cytoskeleton-dependent and -independent host cell invasion by Trypanosoma cruzi is mediated by distinct parasite surface molecules. Infect Immun. 2006;74:5522–5528. doi: 10.1128/IAI.00518-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Huang H, Chan J, Wittner M, Jelicks LA, Morris SA, Factor SM, et al. Expression of cardiac cytokines and inducible form of nitric oxide synthase (NOS2) in Trypanosoma cruzi-infected mice. J Mol Cell Cardiol. 1999;31:75–88. doi: 10.1006/jmcc.1998.0848. [DOI] [PubMed] [Google Scholar]
  • 15.Teixeira MM, Gazzinelli RT, Silva JS. Chemokines, inflammation and Trypanosoma cruzi infection. Trends Parasitol. 2002;18:262–265. doi: 10.1016/s1471-4922(02)02283-3. [DOI] [PubMed] [Google Scholar]
  • 16.Petkova SB, Huang H, Factor SM, Pestell RG, Bouzahzah B, Jelicks LA, et al. The role of endothelin in the pathogenesis of Chagas' disease. Int J Parasitol. 2001;31:499–511. doi: 10.1016/s0020-7519(01)00168-0. [DOI] [PubMed] [Google Scholar]
  • 17.Petkova SB, Tanowitz HB, Magazine HI, Factor SM, Chan J, Pestell RJ, et al. Myocardial expression of endothelin-1 in murine Trypanosoma cruzi infection. Cardiovasc Pathol. 2000;9:257–265. doi: 10.1016/s1054-8807(00)00045-4. [DOI] [PubMed] [Google Scholar]
  • 18.Huang H, Calderon TM, Berman JW, Braunstein VL, Weiss LM, Wittner M, et al. Infection of endothelial cells with Trypanosoma cruzi activates NFκB and induces vascular adhesion molecule expression. Infect Immun. 1999;67:5434–5440. doi: 10.1128/iai.67.10.5434-5440.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Durand JL, Mukherjee S, Commodari F, De Souza AP, Zhao D, Machado FS, et al. Role of NO synthase in the development of Trypanosoma cruzi-induced cardiomyopathy in mice. Am J Trop Med Hyg. 2009;80:782–787. [PMC free article] [PubMed] [Google Scholar]
  • 20.Nakahata N. Thromboxane A2: physiology/pathophysiology, cellular signal transduction and pharmacology. Pharmacol Ther. 2008;118:18–35. doi: 10.1016/j.pharmthera.2008.01.001. [DOI] [PubMed] [Google Scholar]
  • 21.Tanowitz HB, Burns ER, Sinha AK, Kahn NN, Morris SA, Factor SM, et al. Enhanced platelet adherence and aggregation in Chagas' disease: a potential pathogenic mechanism for cardiomyopathy. Am J Trop Med Hyg. 1990;43:274–281. doi: 10.4269/ajtmh.1990.43.274. [DOI] [PubMed] [Google Scholar]
  • 22.Ashton AW, Mukherjee S, Nagajyothi FN, Huang H, Braunstein VL, Desruisseaux MS, et al. Thromboxane A2 is a key regulator of pathogenesis during Trypanosoma cruzi infection. J Exp Med. 2007;204:929–940. doi: 10.1084/jem.20062432. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Ashton AW, Ware GM, Kaul DK, Ware JA. Inhibition of tumor necrosis factor α-mediated NFκB activation and leukocyte adhesion, with enhanced endothelial apoptosis, by G protein-linked receptor (TP) ligands. J Biol Chem. 2003;278:11858–11866. doi: 10.1074/jbc.M210766200. [DOI] [PubMed] [Google Scholar]
  • 24.Gao Y, Yokota R, Tang S, Ashton AW, Ware JA. Reversal of angiogenesis in vitro, induction of apoptosis and inhibition of AKT phosphorylation in endothelial cells by thromboxane A2. Circ Res. 2000;87:739–745. doi: 10.1161/01.res.87.9.739. [DOI] [PubMed] [Google Scholar]
  • 25.Bao Y, Weiss LM, Ma YF, Lisanti MP, Tanowitz HB, Das BC, et al. Molecular cloning and characterization of mitogen-activated protein kinase 2 in Trypanosoma cruzi. Cell Cycle. 2010;9:2888–2896. doi: 10.4161/cc.9.14.12372. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Mukherjee S, Nagajyothi F, Mukhopadhyay A, Machado FS, Belbin TJ, Campos de Carvalho A, et al. Alterations in myocardial gene expression associated with experimental Trypanosoma cruzi infection. Genomics. 2008;91:423–432. doi: 10.1016/j.ygeno.2008.01.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Mukherjee S, Belbin TJ, Spray DC, Iacobas DA, Weiss LM, Kitsis RN, et al. Microarray analysis of changes in gene expression in a murine model of chronic chagasic cardiomyopathy. Parasitol Res. 2003;91:187–196. doi: 10.1007/s00436-003-0937-z. [DOI] [PubMed] [Google Scholar]
  • 28.Soares MB, de Lima RS, Rocha LL, Vasconcelos JF, Rogatto SR, dos Santos RR, et al. Gene expression changes associated with myocarditis and fibrosis in hearts of mice with chronic chagasic cardiomyopathy. J Infect Dis. 2010;202:416–426. doi: 10.1086/653481. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Goldenberg RC, Iacobas DA, Iacobas S, Rocha LL, da Silva de Azevedo Fortes F, Vairo L, et al. Transcriptomic alterations in Trypanosoma cruzi-infected cardiac myocytes. Microbes Infect. 2009;11:1140–1149. doi: 10.1016/j.micinf.2009.08.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Adesse D, Iacobas DA, Iacobas S, Garzoni LR, Meirelles Mde N, Tanowitz HB, et al. Transcriptomic signatures of alterations in a myoblast cell line infected with four distinct strains of Trypanosoma cruzi. Am J Trop Med Hyg. 2010;82:846–854. doi: 10.4269/ajtmh.2010.09-0399. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Imai K, Mimori T, Kawai M, Koga H. Microarray analysis of host gene-expression during intracellular nests formation of Trypanosoma cruzi amastigotes. Microbiol Immunol. 2005;49:623–631. doi: 10.1111/j.1348-0421.2005.tb03654.x. [DOI] [PubMed] [Google Scholar]
  • 32.Moore-Lai D, Rowland E. Microarray data demonstrate that Trypanosoma cruzi downregulates the expression of apoptotic genes in BALB/c fibroblasts. J Parasitol. 2004;90:893–895. doi: 10.1645/GE-146R. [DOI] [PubMed] [Google Scholar]
  • 33.Shigihara T, Hashimoto M, Shindo N, Aoki T. Transcriptome profile of Trypanosoma cruzi-infected cells: simultaneous up and downregulation of proliferation inhibitors and promoters. Parasitol Res. 2008;102:715–722. doi: 10.1007/s00436-007-0819-x. [DOI] [PubMed] [Google Scholar]
  • 34.Nde PN, Johnson CA, Pratap S, Cardenas TC, Kleshchenko YY, Furtak VA, et al. Gene network analysis during early infection of human coronary artery smooth muscle cells by Trypanosoma cruzi and Its gp83 ligand. Chem Biodivers. 2010;7:1051–1064. doi: 10.1002/cbdv.200900320. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Geraghty P, Greene CM, O'Mahony M, O'Neill SJ, Taggart CC, McElvaney NG. Secretory leucocyte protease inhibitor inhibits interferon-gamma-induced cathepsin S expression. J Biol Chem. 2007;282:33389–33395. doi: 10.1074/jbc.M706884200. [DOI] [PubMed] [Google Scholar]
  • 36.Doumas S, Kolokotronis A, Stefanopoulos P. Anti-inflammatory and antimicrobial roles of secretory leukocyte protease inhibitor. Infect Immun. 2005;73:1271–1274. doi: 10.1128/IAI.73.3.1271-1274.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Garg N, Popov VL, Papaconstantinou J. Profiling gene transcription reveals a deficiency of mitochondrial oxidative phosphorylation in Trypanosoma cruzi-infected murine hearts: implications in chagasic myocarditis development. Biochim Biophys Acta. 2003;1638:106–120. doi: 10.1016/s0925-4439(03)00060-7. [DOI] [PubMed] [Google Scholar]
  • 38.Mukherjee S, Machado FS, Huang H, Oz HS, Jelicks LA, Prado CM, et al. Aspirin treatment of mice infected with Trypanosoma cruzi and implications for the pathogenesis of Chagas disease. PLoS One. 2011;6:e16959. doi: 10.1371/journal.pone.0016959. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Mukherjee S, Huang H, Petkova SB, Albanese C, Pestell RG, Braunstein VL, et al. Trypanosoma cruzi infection activates extracellular signal-regulated kinase in cultured endothelial and smooth muscle cells. Infect Immun. 2004;72:5274–5282. doi: 10.1128/IAI.72.9.5274-5282.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Cell Cycle are provided here courtesy of Taylor & Francis

RESOURCES